Perioperative hypertension: a review of current and emerging therapeutic agents,

Journal of Clinical Anesthesia

Volumn 21, Issue 3, 2009, Pages 220-229

  Marik, Paul E ^a   Varon, Joseph ^b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

ACE inhibitor; Beta blocker; Calcium channel blocker; Clevidipine; Esmolol; Hypertension; Hypertensive crisis; Labetalol; Nicardipine; Non cardiac surgery; Surgery

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLEVIDIPINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM;

ANXIETY DISORDER; BRONCHOSPASM; CLINICAL TRIAL; CYANIDE TOXICITY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; EDEMA; FLUSHING; HEADACHE; HEART RATE; HEART SURGERY; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE PAIN; INTRAOPERATIVE PERIOD; MORBIDITY; MORTALITY; MUSCLE SPASM; NAUSEA; NAUSEA AND VOMITING; PARESTHESIA; PERIOPERATIVE PERIOD; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REVIEW; SCALP PRURITUS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TACHYPHYLAXIS; THIOCYANATE TOXICITY;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 65649133611     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinane.2008.09.003     Document Type: Review

References (135)

1. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
2. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289 (2003) 2560-2572
3. Borzecki A.M., Wong A.T., Hickey E.C., Ash A.S., and Berlowitz D.R. Hypertension control: how well are we doing?. Arch Intern Med 163 (2003) 2705-2711
4. Dannenberg A.L., Garrison R.J., and Kannel W.B. Incidence of hypertension in the Framingham Study. Am J Public Health 78 (1988) 676-679
5. Turnbull F., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 9395 (2003) 1527-1535
6. Staessen J.A., Wang J.G., and Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 21 (2003) 1055-1076
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
8. Turnbull F., Neal B., Algert C., et al., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005) 1410-1419
9. Dahlöf B., Sever P.S., Poulter N.R., et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 9489 (2005) 895-906
10. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265 (1991) 3255-3264
11. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 9080 (1997) 757-764
12. Smithwick R.H., and Thompson J.E. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 152 (1953) 1501-1504
13. Khuri S.F., Daley J., Henderson W., et al. The National Veterans Administration Surgical Risk Study: risk adjustment for the comparative assessment of the quality of surgical care. J Am Coll Surg 180 (1995) 519-531
14. Aronson S., Boisvert D., and Lapp W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery. Anesth Analg 94 (2002) 1079-1084
15. Aronson S., Fontes M.L., Miao Y., Mangano D.T., and Investigators of the Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension. Circulation 115 (2007) 733-742
16. Goldman L., and Caldera D.L. Risks of general anesthesia and elective operation in the hypertensive patient. Anesthesiology 50 (1979) 285-292
17. Howell S.J., Sear Y.M., Yeates D., Goldacre M., Sear J.W., and Foëx P. Hypertension, admission blood pressure and perioperative cardiovascular risk. Anaesthesia 51 (1996) 1000-1004
18. Leslie J.B. Incidence and aetiology of perioperative hypertension. Acta Anaesthesiol Scand Suppl 99 (1993) 5-9
19. Rose D.K., Cohen M.M., and DeBoer D.P. Cardiovascular events in the postanesthesia care unit: contribution of risk factors. Anesthesiology 84 (1996) 772-781
20. Mangano D.T., Browner W.S., Hollenberg M., London M.J., Tubau J.F., and Tateo I.M. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med 323 (1990) 1781-1788
21. Stone J.G., Föex P., Sear J.W., Johnson L.L., Khambatta H.J., and Triner L. Risk of myocardial ischaemia during anaesthesia in treated and untreated hypertensive patients. Br J Anaesth 61 (1988) 675-679
22. Mauney Jr. F.M., Ebert P.A., and Sabiston Jr. D.C. Postoperative myocardial infarction: a study of predisposing factors, diagnosis and mortality in a high risk group of surgical patients. Ann Surg 172 (1970) 497-503
23. Prys-Roberts C., Meloche R., and Föex P. Studies of anesthesia in relation to hypertension. I. Cardiovascular responses of treated and untreated patients. Br J Anaesth 43 (1971) 122-137
24. Weksler N., Klein M., Szendro G., et al. The dilemma of immediate preoperative hypertension: to treat and operate, or to postpone surgery?. J Clin Anesth 15 (2003) 179-183
25. Mangano D.T., Layug E.L., Wallace A., and Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 335 (1996) 1713-1720
26. Eagle K.A., Berger P.B., Calkins H., et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery-Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 39 (2002) 542-553
27. Jacka M.J., Schricker T., Warriner B., Boulton A., and Hudson R. More conclusive large-scale trials necessary before recommending use of beta blockade in patients at risk [Letter]. Anesth Analg 98 (2004) 269
28. Devereaux P.J., Yusuf S., Yang H., Choi P.T., and Guyatt G.H. Are the recommendations to use perioperative beta-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence?. CMAJ 171 (2004) 245-247
29. Devereaux P.J., Beattie W.S., Choi P.T., et al. How strong is the evidence for the use of perioperative B blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 331 7512 (2005) 313-321
30. Juul A.B., Wetterslev J., Gluud C., et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ 332 7556 (2006) 1482
31. Poldermans D., Boersma E., Bax J.J., et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 341 (1999) 1789-1794
32. Kertai M.D., Boersma E., Klein J., et al. Optimizing the prediction of perioperative mortality in vascular surgery by using a customized probability model. Arch Intern Med 165 (2005) 898-904
33. Boersma E., Poldermans D., Bax J.J., et al., DECREASE Study Group (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography). Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 285 (2001) 1865-1873
34. Yang H., Raymer K., Butler R., Parlow J., and Roberts R. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 152 (2006) 983-990
35. POISE Study Group, Devereaux P.J., Yang H., Yusuf S., et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 371 9627 (2008) 1839-1847
36. Tepaske R., Velthuis H., Oudemans-van Straaten H.M., et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet 358 9283 (2001) 696-701
37. Braga M., Gianotti L., Nespoli L., Radaelli G., and Di Carlo V. Nutritional approach in malnourished surgical patients: a prospective randomized study. Arch Surg 137 (2002) 174-180
38. Durazzo A.E., Machado F.S., Ikeoka D.T., et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 39 (2004) 967-975
39. Lindenauer P.K., Pekow P., Wang K., Gutierrez B., and Benjamin E.M. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291 (2004) 2092-2099
40. Poldermans D., Bax J.J., Kertai M.D., et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107 (2003) 1848-1851
41. Lopez-Herce J., Dorao P., Ruza F., and de la Oliva P. Treatment of hypertensive crisis with intranasal nifedipine. Crit Care Med 16 (1988) 914
42. O'Leary G., Qureshi S.A., Laganiere S., et al. Intranasal nifedipine for post-bypass hypertension-hemodynamics and pharmacokinetics. Can J Anaesth 37 4 Pt 2 (1990) S144
43. Levy J.H. Treatment of perioperative hypertension. Anesthesiol Clin North Am 17 (1999) 569-570
44. Comfere T., Sprung J., Kumar M.M., et al. Angiotensin system inhibitors in a general surgical population. Anesth Analg 100 (2005) 636-644
45. Coriat P., Richer C., Douraki T., et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology 81 (1994) 299-307
46. Brabant S.M., Bertrand M., Eyraud D., Darmon P.L., and Coriat P. The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists. Anesth Analg 89 (1999) 1388-1392
47. Charlson M.E., MacKenzie C.R., Gold J.P., Ales K.L., Topkins M., and Shires G.T. Intraoperative blood pressure. What patterns identify patients at risk for postoperative complications?. Ann Surg 212 (1990) 567-580
48. Reich D.L., Bennett-Guerrero E., Bodian C.A., Hossain S., Winfree W., and Krol M. Intraoperative tachycardia and hypertension are independently associated with adverse outcome in noncardiac surgery of long duration. Anesth Analg 95 (2002) 273-277
49. Haas C.E., and LeBlanc J.M. Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst Pharm 61 (2004) 1661-1673
50. Weant K.A., Flynn J.D., and Smith K.M. Postoperative hypertension. Orthopedics 27 (2004) 1159-1161
51. Basali A., Mascha E.J., Kalfas I., and Schubert A. Relation between perioperative hypertension and intracranial hemorrhage after craniotomy. Anesthesiology 93 (2000) 48-54
52. Wallach R., Karp R.B., Reves J.G., Oparil S., Smith L.R., and James T.N. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol 46 (1980) 559-565
53. Hines R., Barash P.G., Watrous G., and O'Connor T. Complications occurring in the postanesthesia care unit: a survey. Anesth Analg 74 (1992) 503-509
54. Moller J.T., Johannessen N.W., Espersen K., et al. Randomized evaluation of pulse oximetry in 20,802 patients: II. Perioperative events and postoperative complications. Anesthesiology 78 (1993) 445-453
55. Houston M.C. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 102 3 Pt 1 (1981) 415-430
56. O'Connor D.E. Accelerated acute clonidine withdrawal syndrome during coronary artery bypass surgery. A case report. Br J Anaesth 53 (1981) 431-433
57. Berge K.H., and Lanier W.L. Myocardial infarction accompanying acute clonidine withdrawal in a patient without a history of ischemic coronary artery disease. Anesth Analg 72 (1991) 259-261
58. Neusy A.J., and Lowenstein J. Blood pressure and blood pressure variability following withdrawal of propranolol and clonidine. J Clin Pharmacol 29 (1989) 18-24
59. Maccioli G.A. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology 98 (2003) 575-577
60. Farag E., Chahlavi A., Argalious M., et al. Using dexmedetomidine to manage patients with cocaine and opioid withdrawal, who are undergoing cerebral angioplasty for cerebral vasospasm. Anesth Analg 103 (2006) 1618-1620
61. Baddigam K., Russo P., Russo J., and Tobias J.D. Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients. J Intensive Care Med 20 (2005) 118-123
62. Bussmann W.D., Kenedi P., von Mengden H.J., Nast H.P., and Rachor N. Comparison of nitroglycerin with nifedipine in patients with hypertensive crisis or severe hypertension. Clin Investig 70 (1992) 1085-1088
63. Estafanous F.G. Hypertension in the surgical patient: management of blood pressure and anesthesia. Cleve Clin J Med 56 (1989) 385-393
64. Shepherd A.M., Ludden T.M., McNay J.L., and Lin M.S. Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther 28 (1980) 804-811
65. Shepherd A.M., and Irvine N.A. Differential hemodynamic and sympathoadrenal effects of sodium nitroprusside and hydralazine in hypertensive subjects. J Cardiovasc Pharmacol 8 (1986) 527-533
66. Powers D.R., Papadakos P.J., and Wallin J.D. Parenteral hydralazine revisited. J Emerg Med 16 (1998) 191-196
67. Magee L.A., Cham C., Waterman E.J., Ohlsson A., and von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327 7421 (2003) 955-960
68. Marik P.E., and Varon J. Hypertensive crises: challenges and management. Chest 131 (2007) 1949-1962
69. Mann T., Cohn P.F., Holman L.B., Green L.H., Markis J.E., and Phillips D.A. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation 57 (1978) 732-738
70. Cohn J.N., Franciosa J.A., Francis G.S., et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 306 (1982) 1129-1135
71. Elliott W.J., Weber R.R., Nelson K.S., et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation 81 (1990) 970-977
72. Hartmann A., Buttinger C., Rommel T., Czernicki Z., and Trtinjiak F. Alteration of intracranial pressure, cerebral blood flow, autoregulation and carbondioxide-reactivity by hypotensive agents in baboons with intracranial hypertension. Neurochirurgia (Stuttg) 32 (1989) 37-43
73. Kondo T., Brock M., and Bach H. Effect of intra-arterial sodium nitroprusside on intracranial pressure and cerebral autoregulation. Jpn Heart J 25 (1984) 231-237
74. Griswold W.R., Reznik V., and Mendoza S.A. Nitroprusside-induced intracranial hypertension [Letter]. JAMA 246 (1981) 2679-2680
75. Anile C., Zanghi F., Bracali A., Maira G., and Rossi G.F. Sodium nitroprusside and intracranial pressure. Acta Neurochi (Wien) 58 (1981) 203-211
76. Pasch T., Schulz V., and Hoppelshäuser G. Nitroprusside-induced formation of cyanide and its detoxication with thiosulphate during deliberate hypotension. J Cardiovasc Pharmacol 5 (1983) 77-85
77. Cheung A.T., Cruz-Shiavone G.E., Meng Q.C., et al. Cardiopulmonary bypass, hemolysis, and nitroprusside-induced cyanide production. Anesth Analg 105 (2007) 29-33
78. Nakamura Y., Yasuda M., Fujimori H., Kiyono M., and Pan-Hou H. Cytotoxic effect of sodium nitroprusside on PC12 cells. Chemosphere 34 (1997) 317-324
79. Gobbel G.T., Chan T.Y., and Chan P.H. Nitric oxide- and superoxide-mediated toxicity in cerebral endothelial cells. J Pharmacol Exp Ther 282 (1997) 1600-1607
80. Rauhala P., Khaldi A., Mohanakumar K.P., and Chiueh C.C. Apparent role of hydroxyl radicals in oxidative brain injury induced by sodium nitroprusside. Free Radic Biol Med 24 (1998) 1065-1073
81. Niknahad H., and O'Brien P.J. Involvement of nitric oxide in nitroprusside-induced hepatocyte cytotoxicity. Biochem Pharmacol 51 (1996) 1031-1039
82. Robin E.D., and McCauley R. Nitroprusside-related cyanide poisoning. Time (long past due) for urgent, effective interventions. Chest 102 (1992) 1842-1845
83. Kross R.A., Ferri E., Leung D., et al. A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. Anesth Analg 91 (2000) 904-909
84. Murphy M.B., Murray C., and Shorten G.D. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345 (2001) 1548-1557
85. Bodmann K.F., Tröster S., Clemens R., and Schuster H.P. Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. Clin Investig 72 (1993) 60-64
86. Munger M.A., Rutherford W.F., Anderson L., et al. Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Crit Care Med 18 (1990) 502-504
87. White W.B., Radford M.J., Gonzalez F.M., Weed S.G., McCabe E.J., and Katz A.M. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol 11 (1988) 1118-1123
88. Tumlin J.A., Dunbar L.M., Oparil S., et al. Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med 7 (2000) 653-662
89. Goldberg M.E., Cantillo J., Nemiroff M.S., et al. Fenoldopam infusion for the treatment of postoperative hypertension. J Clin Anesth 5 (1993) 386-391
90. Shusterman N.H., Elliott W.J., and White W.B. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 95 (1993) 161-168
91. White W.B., and Halley S.E. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med 149 (1989) 870-874
92. Reisin E., Huth M.M., Nguyen B.P., Weed S.G., and Gonzalez F.M. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension 15 2 Suppl (1990) I59-I62
93. Lund-Johansen P. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. Drugs 28 Suppl 2 (1984) 35-50
94. Kanto J., Allonen H., Kleimola T., and Mäntylä R. Pharmacokinetics of labetalol in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 19 (1981) 41-44
95. Goldberg M.E., Clark S., Joseph J., et al. Nicardipine versus placebo for the treatment of postoperative hypertension. Am Heart J 119 2 Pt 2 (1990) 446-450
96. Pearce C.J., and Wallin J.D. Labetalol and other agents that block both alpha- and beta-adrenergic receptors. Cleve Clin J Med 61 (1994) 59-69
97. Wallin J.D. Adrenoreceptors and renal function. J Clin Hypertens 1 (1985) 171-178
98. Marx P.G., and Reid D.S. Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol 8 Suppl 2 (1979) 233S-238S
99. Olsen K.S., Svendsen L.B., Larsen F.S., and Paulson O.B. Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth 75 (1995) 51-54
100. Rosei E.A., Trust P.M., Brown J.J., Lever A.F., and Robertson J.I. Letter: Intravenous labetalol in severe hypertension. Lancet 2 7944 (1975) 1093-1094
101. Cruise C.J., Skrobik Y., Webster R.E., Marquez-Julio A., and David T.E. Intravenous labetalol versus sodium nitroprusside for treatment of hypertension postcoronary bypass surgery. Anesthesiology 71 (1989) 835-839
102. Malsch E., Katonah J., Gratz I., and Scott A. The effectiveness of labetalol in treating postoperative hypertension. Nurse Anesth 2 (1991) 65-71
103. Sladen R.N., Klamerus K.J., Swafford M.W., et al. Labetalol for the control of elevated blood pressure following coronary artery bypass grafting. J Cardiothorac Anesth 4 (1990) 210-221
104. Geniton D.J. A comparison of the hemodynamic effects of labetalol and sodium nitroprusside in patients undergoing carotid endarterectomy. AANA J 58 (1990) 281-287
105. Leslie J.B., Kalayjian R.W., Sirgo M.A., Plachetka J.R., and Watkins W.D. Intravenous labetalol for treatment of postoperative hypertension. Anesthesiology 67 (1987) 413-416
106. Balser J.R., Martinez E.A., Winters B.D., et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology 89 (1998) 1052-1059
107. Platia E.V., Michelson E.L., Porterfield J.K., and Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 63 (1989) 925-929
108. Stumpf J.L. Drug therapy of hypertensive crises. Clin Pharm 7 (1988) 582-591
109. Smerling A., and Gersony W.M. Esmolol for severe hypertension following repair of aortic coarctation. Crit Care Med 18 (1990) 1288-1290
110. Gray R.J., Bateman T.M., Czer L.S., Conklin C., and Matloff J.M. Use of esmolol in hypertension after cardiac surgery. Am J Cardiol 56 (1985) 49F-56F
111. Gray R.J., Bateman T.M., Czer L.S., Conklin C., and Matloff J.M. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am J Cardiol 59 (1987) 887-891
112. Muzzi D.A., Black S., Losasso T.J., and Cucchiara R.F. Labetalol and esmolol in the control of hypertension after intracranial surgery. Anesth Analg 70 (1990) 68-71
113. Gray R.J. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker. Chest 93 (1988) 398-403
114. Lowenthal D.T., Porter R.S., Saris S.D., et al. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol 56 (1985) 14F-18F
115. Reynolds R.D., Gorczynski R.J., and Quon C.Y. Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol 26 Suppl A (1986) A3-A14
116. Varon J., and Marik P.E. The diagnosis and management of hypertensive crises. Chest 118 (2000) 214-227
117. Turlapaty P., Vary R., and Kaplan J.A. Nicardipine, a new intravenous calcium antagonist: a review of its pharmacology, pharmacokinetics, and perioperative applications. J Cardiothorac Anesth 3 (1989) 344-355
118. Efficacy and safety of intravenous nicardipine in the control of postperative hypertension. IV Nicardipine Study Group. Chest 99 (1991) 393-398
119. Schillinger D. Nifedipine in hypertensive emergencies: a prospective study. J Emerg Med 5 (1987) 463-473
120. David D., Dubois C., and Loria Y. Comparison of nicardipine and sodium nitroprusside in the treatment of paroxysmal hypertension following aortocoronary bypass surgery. J Cardiothorac Vasc Anesth 5 (1991) 357-361
121. Halpern N.A., Goldberg M., Neely C., et al. Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med 20 (1992) 1637-1643
122. Dorman T., Thompson D.A., Breslow M.J., Lipsett P.A., and Rosenfeld B.A. Nicardipine versus nitroprusside for breakthrough hypertension following carotid endarterectomy. J Clin Anesth 13 (2001) 16-19
123. Halpern N.A., Sladen R.N., Goldberg J.S., et al. Nicardipine infusion for postoperative hypertension after surgery of the head and neck. Crit Care Med 18 (1990) 950-955
124. Vincent J.L., Berlot G., Preiser J.C., Engelman E., Dereume J.P., and Khan R.J. Intravenous nicardipine in the treatment of postoperative arterial hypertension. J Cardiothorac Vasc Anesth 11 (1997) 160-164
125. Rodriguez G., and Varon J. Clevidipine: a unique agent for the critical care practitioner. Crit Care Shock 9 (2006) 9-15
126. Bailey J.M., Lu W., Levy J.H., et al. Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology 96 (2002) 1086-1094
127. Ericsson H., Fakt C., Jolin-Mellgård A., et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol 47 (1999) 531-538
128. Ericsson H., Tholander B., and Regårdh C.G. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci 8 (1999) 29-37
129. Nordlander M., Björkman J.A., Regårdh C.G., and Thalén P. Pharmacokinetics and hemodynamic effects of an ultrashort-acting calcium antagonist. Br J Anaesth 76 Suppl 1 (1996) A24
130. Kieler-Jensen N., Jolin-Mellgård A., Nordlander M., and Ricksten S.E. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand 44 (2000) 186-193
131. Segawa D., Sjöquist P.O., Wang Q.D., Gonon A., and Rydén L. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II. J Cardiovasc Pharmacol 40 (2002) 339-345
132. Segawa D., Sjöquist P.O., Wang Q.D., Gonon A., Nordlander M., and Rydén L. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine. J Cardiovasc Pharmacol 36 (2000) 338-343
133. Stephens C.T., and Jandhyala B.S. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens 24 (2002) 301-313
134. Powroznyk A.V., Vuylsteke A., Naughton C., et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 20 (2003) 697-703
135. Aronson S., Dyke C.M., Kereiakes D., Cheung A., Stierer K., and Newman M. Blood pressure control with clevidipine compared to nitroglycerin in the treatment of perioperative hypertension: primary results from the randomized ECLIPSE trial. [Abstract]. J Am Coll Cardiol 49 9 Suppl A (2007) 315A-419A